Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3 Conference Paper uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Clinical Trials as Topic
  • Drug Approval
  • Prostatic Neoplasms, Castration-Resistant
  • Research Design

abstract

  • PCWG3 moves drug development closer to unmet needs in clinical practice by focusing on disease manifestations most likely to affect prognosis adversely for therapeutics tested in both nonmetastatic and metastatic CRPC populations. Consultation with regulatory authorities is recommended if a trial is intended to seek support for drug approval.

authors

publication date

  • April 20, 2016

Research

keywords

  • Conference Paper

Identity

Language

  • eng

PubMed Central ID

  • PMC4872347

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.64.2702

PubMed ID

  • 26903579

Additional Document Info

start page

  • 1402

end page

  • 18

volume

  • 34

number

  • 12